Fig. 5From: SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid CancerSoLAT was most efficiently induced tumor shrinkage in GSP2 and GSP3 xenografts model. a and d SoLAT suppressed tumor growth better than individual treatments with sorafenib or lenvatinib. b and e Sorafenib or lenvatinib treatment did not significantly affect the body weight of treated mice. No evidence of systemic toxicity or treatment-related death was observed in any group. c and f The SoLAT group showed significantly smaller tumor volumes compared to the individual treatment groupsBack to article page